To investigate further the role of oncogenic BRAF in mediating response to BOLD-100, we evaluated the effect of BOLD-100 on viability of the parental BRAFMT VACO432 colorectal cancer cell line and its isogenic VT1 clone with a disrupted BRAFV600E allele [Fig. 1E (left); ref. 24]. The gene discussed is BRAF; the disease is colorectal cancer.